InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
T+90 hit rate
29%
T+90 mean return
-3.1%
Across 14 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by philippe monnot, Supervisory Board Chairman. Insider active across 1 company, notably CROSSJECT. Aggregated, 14 disclosures have been published. Breakdown: 3 buys · 0 sell. Total volume traded: €1m. Activity tracked since 18 February 2021. The latest transaction was filed on 6 June 2024 (Souscription). Regulator: AMF. All data is accessible without signup.
Declarations14 total
10,074 shares@ €1.8480.5% of flowActionEuronext Growth Paris2024DD970268
22,859 shares@ €3.302.0% of flowActionEuronext Growth Paris2023DD887728
373,942 shares@ €2.7026.2% of flowActionEuronext Paris2022DD866409
Ideal exit: 10 Jul 2023 (T+270)
5,057 shares@ €3.156.0% of flowActionEuronext Paris2022DD857601
1,137,019 shares@ €1.618347.7% of flowActionEuronext Paris2022DD848529
269,070 shares@ €3.0020.9% of flowActionEuronext Paris2022DD848530
3,519 shares@ €3.000.3% of flowActionEuronext Paris2022DD848532
Ideal exit: 18 Mar 2023 (T+270)
6,000 shares@ €3.440.5% of flowActionEuronext Paris2022DD848533
Ideal exit: 20 Mar 2023 (T+270)
2,825 shares@ €1.770.1% of flowActionEuronext Paris2022DD837795
11,765 shares@ €1.700.5% of flowActionEuronext Paris2022DD837800
19,531 shares@ €2.5618.8% of flowActionEuronext Paris2022DD817040
19,011 shares@ €2.631.3% of flowActionEuronext Growth Paris2021DD799766
20,661 shares@ €2.4218.8% of flowActionEuronext Growth Paris2021DD760380
50,505 shares@ €2.9756.4% of flowActionEuronext Paris2021DD733275
14 of 14 declarations
About philippe monnot
Philippe Monnot is a recognized figure in French entrepreneurial investment and the governance of innovative companies. At CROSSJECT, he serves as Chairman of the Supervisory Board, a role that places him at the center of the company’s long-term governance framework. CROSSJECT states that he is also one of the company’s historic backers through Gemmes Venture, the investment vehicle he co-founded in 1999 and co-leads. Gemmes Venture was CROSSJECT’s first shareholder, underscoring Monnot’s early and lasting involvement in the company’s development. A graduate of emlyon business school, Monnot has built a profile as an investor and ecosystem builder with a strong focus on healthcare, alongside exposure to digital services, fintech and cleantech. CROSSJECT’s governance materials indicate that Gemmes Venture was among the founding shareholders of several healthcare-related companies, including ASTEN SANTÉ, H2AD TELEHEALTH and VIVALIB. This background points to substantial expertise in spotting high-potential ventures, structuring equity investments, and supporting technology and healthcare businesses across different stages of growth. Within CROSSJECT’s ecosystem, Monnot represents stable shareholding and a governance mindset focused on industrial and regulatory value creation. CROSSJECT develops ZENEO®, a needle-free auto-injection platform, and the Supervisory Board plays a key role in supporting strategy, financing, clinical milestones and industrial execution. Monnot’s position therefore reflects the combination of investor perspective, commitment to entrepreneurship and long-term involvement in high-technology healthcare businesses. His career illustrates an ability to align capital, governance discipline and strategic support in order to help scale innovative companies.
